XML 26 R15.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets	6 Months Ended
Goodwill and Intangible Assets	Jun. 30, 2025
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Note 6 — Goodwill and Intangible Assets The total amount of goodwill reported was $24.0 billion at June 30, 2025, and $23.1 billion at December 31, 2024. The amount of goodwill related to reportable segments at June 30, 2025, was $2.7 billion for the Established Pharmaceutical Products segment, $285 million for the Nutritional Products segment, $3.6 billion for the Diagnostic Products segment, and $17.3 billion for the Medical Devices segment. Foreign currency translation adjustments increased goodwill by $836 million in the first six months of 2025. There were no reductions of goodwill relating to impairments in the first six months of 2025. The gross amount of amortizable intangible assets, primarily product rights and technology, was $27.6 billion as of June 30, 2025, and $27.1 billion as of December 31, 2024. Accumulated amortization was $22.4 billion and $21.3 billion as of June 30, 2025, and December 31, 2024, respectively. In the first six months of 2025, intangible assets, net of amortization, increased $87 million due to foreign currency translation. Abbott’s estimated annual amortization expense for intangible assets is approximately $1.7 billion in 2025, $1.5 billion in 2026, $1.2 billion in 2027, $0.7 billion in 2028 and $0.6 billion in 2029. Indefinite-lived intangible assets, which relate to in-process research and development (IPR&D) acquired in a business combination, were $789 million and $784 million as of June 30, 2025, and December 31, 2024, respectively.